Interesting on their mean survival #'s since their overall response rate seems a lot lower. ABII had an overall response rate of 70% (5% CR + 39% PR + 16% SD) while THLD had 92% (3% CR 24% PR 65% SD)
Odd that ABII had so many tumor shrinkage and complete responses (44%) but less then 1/3 of the people where there wasn't shrinkage had a halt of progression. Maybe the people that ABII's drug worked on had unusally high levels of the SPARC biomarker. It seems that if the drug helped at all it helped a lot - but it mostly didn't work on the average patient.
In contrast TH-302 (THLD's drug) seemed to have a much more broad effect but on a much more broad patient population (ABII's patients all hand seleced for that SPARC biomarker)
Seems like both have some effectiveness but on a different patient population and ABRAXANE seems to be very potent if it works but for MOST people with the SPARC marker if it doesnt shrink there wont be any effect, whereas TH-302 seems to be more broad in the people that have a benefit, with more poepple having a benefit, but the benefit isn't as extreme.
Market Data 
Markets 
AI
